Physician profile
Asghar Ali
NPI 1376070383
$841.83
in general payments reported to CMS, 2019-2025
10 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.07 · 2023: $18.19 · 2024: $352 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $175.23 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Kyowa Kirin, INC. | $123.55 | 2024 | |
| Novo Nordisk INC | $118.09 | 2025 | Ozempic |
| Intuitive Surgical, INC. | $90.34 | 2025 | |
| Abbvie INC. | $90.20 | 2025 | |
| Pfizer INC. | $71.80 | 2023-2025 | |
| W. L. Gore & Associates, INC. | $61.52 | 2025 | Gore Tag Conformable Thoracic Endoprosthesis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.87 | 2024-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $47.07 | 2021 | |
| Glaxosmithkline, LLC. | $16.16 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asghar Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.